San Francisco, California – November 3, 2025
Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage biopharmaceutical company focused on harnessing the immune system to combat infectious diseases, announced the completion of enrollment in the Phase 3 ECLIPSE-1 clinical trial, part of its global ECLIPSE registrational program for Chronic Hepatitis Delta (CHD). This milestone marks a pivotal advancement toward addressing one of the world’s most severe and underserved viral liver diseases, positioning Vir closer to its goal of delivering first-in-class combination therapy for patients living with CHD.
Science Significance
The ECLIPSE-1 study is designed to evaluate the efficacy and safety of tobevibart and elebsiran, an innovative dual-mechanism combination therapy targeting the hepatitis delta virus (HDV). Tobevibart, a broadly neutralizing monoclonal antibody, blocks viral entry and accelerates immune clearance, while elebsiran, a small interfering RNA (siRNA) molecule, silences viral replication at the genetic level. Together, they represent a new paradigm in antiviral science, tackling the HDV life cycle from multiple fronts. Building upon Phase 2 SOLSTICE data that showed rapid viral suppression to undetectable levels, this Phase 3 trial could establish a new scientific benchmark for functional cures in viral hepatitis.
Regulatory Significance
Vir’s ECLIPSE program carries major regulatory weight. Both tobevibart and elebsiran have been granted FDA Breakthrough Therapy Designation and Fast Track status, as well as EMA PRIME and Orphan Drug designations—highlighting the urgent medical need and transformative potential of this therapy. The ECLIPSE-1 and ECLIPSE-2 Phase 3 trials are structured to generate registrational data for global regulatory submissions, while ECLIPSE-3 will provide critical data to support market access and reimbursement strategies. This comprehensive approach underscores Vir’s commitment to meeting global regulatory expectations and ensuring patients gain access to innovative antiviral treatments as swiftly as possible.
Advertisement
Business Significance
The completion of Phase 3 enrollment represents a strategic and financial inflection point for Vir Biotechnology. With a strong track record in developing immune-powered therapies, the company is poised to enter the final stage of clinical validation for its hepatitis delta program. This advancement enhances investor confidence, positions Vir as a leader in viral immunotherapy, and strengthens its commercial pipeline across infectious disease and oncology programs. The trial’s success could open a multi-billion-dollar market in liver diseases and reinforce the company’s broader mission to redefine antiviral care through immunological innovation.
Patients’ Significance
For the estimated 15–20 million people worldwide living with chronic hepatitis delta, this development brings long-awaited hope. The disease, caused by HDV superinfection in individuals with hepatitis B, is the most aggressive form of viral hepatitis, leading to rapid progression to cirrhosis, liver failure, or cancer within years. With no FDA-approved therapies in the U.S. and limited global options, patients face dire prognoses. The combination of tobevibart and elebsiran could finally deliver a functional antiviral solution that stops disease progression and restores long-term liver health—transforming the treatment landscape for a population in urgent need.
Policy Significance
From a policy standpoint, Vir’s ECLIPSE program supports global health priorities aimed at achieving the World Health Organization’s 2030 goal of eliminating viral hepatitis as a public health threat. The program’s design also integrates strategies for equitable global access, with a Phase 2b (ECLIPSE-3) trial dedicated to generating data that informs reimbursement frameworks and regional approval pathways. Vir’s collaboration with regulators, payors, and health agencies sets a model for how science-driven, policy-aligned drug development can accelerate the availability of life-saving treatments worldwide.
With the ECLIPSE-1 Phase 3 trial now fully enrolled, Vir Biotechnology stands on the threshold of delivering a groundbreaking therapy for chronic hepatitis delta, one of the last major unmet needs in viral hepatology. The dual-mechanism approach of tobevibart and elebsiran exemplifies the future of antiviral innovation—where immunology, RNA science, and regulatory excellence converge to advance global health. As the company prepares for data readouts and regulatory submissions, this milestone reaffirms Vir’s mission to power the immune system to transform lives and its role as a pioneer in the fight against infectious disease.
Source: Vir Biotechnology, Inc. press release
